Wockhardt Eyes $7 Bn Mkt For Its Antibiotic Zaynich

New Delhi: Drugmaker Wockhardt said its novel antibiotic Zaynich has an addressable market opportunity of $7 billion in the US and Europe.

The company said it has completed a pre-NDA (non-disclosure agreement) meeting with the USFDA in May 2025. Filing to the USFDA is slated in the second quarter of the current fiscal with potential launch in FY2026-27, Wockhardt Ltd said in a regulatory filing. The company plans for regulatory approval for the product in Europe and emerging markets in the second half of the current financial year, it added.

In May, the drug firm reported a narrowing of consolidated net loss at Rs45 crore in the fourth quarter ended March 31, 2025. The company had reported a net loss of Rs177 crore in the January-March quarter of FY24. Revenue from operations rose to Rs743 crore in the fourth quarter as compared to Rs700 crore in the year-ago period.